BridgeMD
Remifentanil versus rocuronium for optimizing video laryngoscopy assisted tracheal intubation in patients undergoing general anaesthesia - a multicentre randomised controlled trial The ROCVIDEO trial
EU CTIS ID: 2025-521405-40-01
What this study is testing
This trial aims to assess the benefits and harms of remifentanil versus rocuronium for optimising tracheal intubation conditions in adult patients undergoing tracheal intubation using video laryngoscopy.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Adults ≥ 18 years
- - Undergoing general anaesthesia requiring oro-tracheal intubation
- - Absence of indication for rapid sequence induction
- - American Society of Anesthesiologists (ASA) physical status score I - III
You likely can't join if
- - Known allergies or contraindications to rocuronium (e.g. neuromuscular disease) or remifentanil
- - Awake intubation
- - Double-lumen endotracheal tube
- - Oral, pharyngeal, and laryngeal surgery
- - Surgical contraindication for NMBAs (e.g. use of nerve stimulator)
- - Patients who do not understand Danish or are unable to give informed consent
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.